WALTHAM, Mass.–(BUSINESS WIRE)–Adagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize coronaviruses, today announced that Tillman Gerngross, Ph.D., chief executive officer, and Jane Henderson, chief financial officer, will participate in one-on-one investor meetings during the Cowen 41st Annual Health Care Conference on Monday, March 1, 2021.
About Adagio Therapeutics
Adagio is developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV1 and additional pre-emergent coronaviruses. Our portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and are designed to provide patients and clinicians with an unsurpassed combination of potency, breadth, durable protection (via half-life extension), manufacturability, tolerability, and affordability. Our portfolio of SARS-CoV-2 antibodies includes multiple, non-competing antibodies with distinct binding epitopes. Independent third-party analysis shows that our lead antibody ADG20 exceeds the potency and coverage of all current clinical SARS-CoV-2 antibody programs. We plan to advance ADG20, which is currently in a Phase 1 study, aggressively through global clinical trials for both the prevention (EVADE) and treatment (STAMP) of symptomatic COVID-19 and anticipate data from both prevention and treatment clinical trials in 2021. Adagio has secured manufacturing capacity for the production of ADG20 with third party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch. For more information: www.adagiotx.com
Lindsay G. Deefholts